Beam Therapeutics Q1 EPS $(0.91) Beats $(1.09) Estimate, Sales $31.738M Beat $10.977M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.09) by 16.51 percent. This is a 26.02 percent increase over losses of $(1.23) per share from
